Brief Title
Adipocytokines in Endometrial Cancer
Official Title
Profile of Adipocytokines in Patients With Endometrial Cancer: Focus on Various Types of Adipose Tissues
Brief Summary
Endometrial cancer incidence rates were increasing in the past two decades with a continuous
rising trend in Taiwan. Uterine cancer was attributable to obesity based on their association
with excess body weight in most epidemiological cohort studies. However, the prevalence of
obesity was lower in Taiwan.Therefore, we will study if adipose tissues depots in different
locations of body could reflect or correlate the pathogenesis of endometrial cancer.
Detailed Description
Besides lipid metabolism, adipose tissue plays import roles in regulation of hormones,
adipokines, cytokines and immunocytes. Adipose tissue is now known as endocrine organ which
to express and secrete a variety of bioactive peptides, known as adipokines. We will evaluate
the difference various adipocytokines between visceral and subcutaneous adipose tissues
between women with benign lesions and endometrial cancer. We will study the inter-individual
differences in adipocytokines between two types of adipose tissues and their correlation with
image quantification.
Study Type
Interventional
Primary Outcome
Adipocytokines profile
Condition
Endometrial Cancer
Intervention
Excise adipose tissue
Study Arms / Comparison Groups
Benign
Description: Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5*5 cm omental fat and one 3*3 cm subcutaneous adipose tissue during surgery.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Procedure
Estimated Enrollment
200
Start Date
September 1, 2021
Completion Date
July 29, 2022
Primary Completion Date
July 29, 2022
Eligibility Criteria
Inclusion Criteria:
Women diagnosed with primary endometrial cancer and undergo surgery, with or without
adjuvant therapy in our hospital (EmCa group); women received surgery for benign pelvic
lesions in our hospital (control group)
Exclusion Criteria:
Women with an underlying malignancy or any concomitant malignancy, prior chemotherapy or
radiation before diagnosis of endometrial cancer, history of autoimmune diseases or
immunosuppressive agent use
Gender
Female
Ages
20 Years - 80 Years
Accepts Healthy Volunteers
No
Contacts
, 886-23123456, [email protected]
Administrative Informations
NCT ID
NCT05018195
Organization ID
202106074RIND
Responsible Party
Sponsor
Study Sponsor
National Taiwan University Hospital
Study Sponsor
, ,
Verification Date
August 2021